Year: 2012
Type: article
Abstract: Age-related Macular Degeneration (AMD) is a serious eye disease. Two similar drugs, Lucentis and Avastin, are available to slow the progression of wet AMD. Research has been carried out on the highly profitable drug Lucentis, so governments have licensed it for use, whereas equivalent research and formal licensing of Avastin for treatment of eye disease has been delayed and discouraged. This is a case illustrating the problem of undone science: research in socially beneficial areas may be neglected for commercial or political reasons.
Author: Tommy Cleary
Institution: University of Wollongong
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: green
OpenAlex ID: W1570612798